VEGFA and renal cell carcinoma: Therapeutic approaches for treatment of RCC include the VEGF antibody bevacizumab, mTOR inhibitors temsirolimus and everolimus, the PD-1 checkpoint inhibitor nivolumab, and tyrosine kinase inhibitors (TKI) such as sunitinib, pazopanib, sorafenib, levatinib, and axitinib [7].